Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Mitophagy preserves microvascular structure and function during myocardial
ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect …

Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …

Background Empagliflozin has been reported to protect endothelial cell function, regardless
of diabetes status. However, the role of empagliflozin in microvascular protection during …

The vascular endothelium is a dynamic, functionally complex organ, modulating multiple
biological processes, including vascular tone and permeability, inflammatory responses …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

The vascular cellular adhesion molecule-1 (VCAM-1) is a protein that canonically
participates in the adhesion and transmigration of leukocytes to the interstitium during …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …